Express News | Mainz Biomed Shares Are Trading Higher on Possible Continued Strength After the Company Reported a Year-over-year Increase in FY24 EPS Results on Tuesday
Mainz Biomed 2024 Loss/Shr $22.36 >MYNZ
Mainz Biomed 2024 Rev $893,991 >MYNZ
Express News | Mainz Biomed FY24 EPS ($22.36) Up From ($64.76) YoY; Revenue $893.9K Down From $895.4K YoY
Mainz Biomed Reports FY24 EPS ($22.36) Vs ($64.76) Last Year
Mainz Biomed | 6-K: Report of foreign private issuer (related to financial reporting)
Press Release: Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Mainz Biomed Reports 2024 Financial Results and Provides Corporate Update
Mainz Biomed | 20-F: FY2024 Annual Report
Maxim Group Maintains Mainz Biomed(MYNZ.US) With Buy Rating, Maintains Target Price $14
Mainz Biomed Enrolls First Patient In EAArly DETECT 2 Clinical Study, Says Study On Track To Report Top-Line Results In Q4 2025
Mainz Biomed Enrolls First Patient in Its EAArly DETECT 2 Clinical Study
Strategic Collaboration and Innovative Biomarkers Drive Buy Rating for Mainz Biomed
Mainz Biomed, Liquid Biosciences Make Discovery of MRNA Biomarkers
Mainz Biomed Enters Agreement With Liquid Biosciences To Develop Blood Test For Pancreatic Cancer Detection
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of MRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift From Screening to Prevention
Mainz Biomed Partners With Labor Team W Ag to Launch ColoAlert Colorectal Cancer Screening Test in Switzerland
Mainz Biomed Expands Into Switzerland With Labor Team W
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday